P
Petrus J. de Vries
Researcher at University of Cape Town
Publications - 156
Citations - 8287
Petrus J. de Vries is an academic researcher from University of Cape Town. The author has contributed to research in topics: Autism & Autism spectrum disorder. The author has an hindex of 40, co-authored 140 publications receiving 6220 citations. Previous affiliations of Petrus J. de Vries include University of Cambridge & Royal Sussex County Hospital.
Papers
More filters
Journal ArticleDOI
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler,J. Christopher Kingswood,Elżbieta Radzikowska,Bernard A. Zonnenberg,Michael Frost,Elena Belousova,Matthias Sauter,Norio Nonomura,Susanne Brakemeier,Petrus J. de Vries,Vicky Whittemore,David Chen,Tarek Sahmoud,Gaurav D. Shah,Jeremie Lincy,David Lebwohl,Klemens Budde +16 more
TL;DR: Everolimus reduced angiomyolipoma volume with an acceptable safety profile, suggesting it could be a potential treatment for angiomeolipomas associated with tuberous sclerosis.
Journal ArticleDOI
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz,Elena Belousova,Steven Sparagana,E. Martina Bebin,Michael Frost,Rachel Kuperman,Olaf Witt,Michael Kohrman,J. Robert Flamini,Joyce Y. Wu,Paolo Curatolo,Petrus J. de Vries,Vicky Whittemore,Elizabeth A. Thiele,James Ford,Gaurav D. Shah,Helene Cauwel,David Lebwohl,Tarek Sahmoud,Sergiusz Jozwiak +19 more
TL;DR: These results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberousclerosis.
Journal ArticleDOI
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
Jacqueline A. French,John A. Lawson,Zuhal Yapici,Hiroko Ikeda,Tilman Polster,Rima Nabbout,Paolo Curatolo,Petrus J. de Vries,Dennis J. Dlugos,Noah Berkowitz,Maurizio Voi,Severine Peyrard,Diana Pelov,David Neal Franz +13 more
TL;DR: Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo in patients with tuberous sclerosis complex and treatment-resistant seizures.
Journal ArticleDOI
Neurological and neuropsychiatric aspects of tuberous sclerosis complex
TL;DR: Continuity of clinical care and ongoing monitoring is paramount, and particular attention is needed to plan transition of patient care from childhood to adult services, as well as management of the neurological and neuropsychiatric manifestations of the disorder.
Journal ArticleDOI
Developmental disabilities among children younger than 5 years in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Bolajoko O. Olusanya,Adrian Davis,Donald Wertlieb,Nem-Yun Boo,M.K.C. Nair,Ricardo Halpern,Hannah Kuper,Cecilia Breinbauer,Petrus J. de Vries,Melissa Gladstone,Neal Halfon,Vijaya Kancherla,Mphelekedzeni C. Mulaudzi,Angelina Kakooza-Mwesige,Felix Akpojene Ogbo,Jacob Olusegun Olusanya,Andrew N Williams,Scott M. Wright,Helena Manguerra,Alison Smith,Michelle Echko,Chad Ikeda,Angela Liu,Anoushka Millear,Katherine E. Ballesteros,Emma Nichols,Holly E. Erskine,Damian Santomauro,Zane Rankin,Mari Smith,Harvey Whiteford,Helen E Olsen,Nicholas J Kassebaum +32 more
TL;DR: The global burden of developmental disabilities has not significantly improved since 1990, suggesting inadequate global attention on the developmental potential of children who survived childhood as a result of child survival programmes, particularly in sub-Saharan Africa and south Asia.